RxDoctor Payments DataLook up a doctor →

David Hotchkiss, MD

Cardiovascular Disease · Port Charlotte, FLNPI 1548377435

Payments from drug & device makers

$3,985,016in general payments, 2019–2025

Across 708 payments — averaging $5628.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.9M
  • Janssen Research & Development, LLC$754K
  • Novartis$680K
  • AstraZeneca$191K
  • Amgen$144K
  • Merck$105K
  • plus $215K from 44 others
$33,375in research payments, 2019–2025

Across 5 payments — averaging $6674.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$33K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly44$1,897,216
Janssen Research & Development, LLC39$753,899
Novartis69$679,580
AstraZeneca14$190,881
Amgen31$144,037
Merck25$104,872
Boehringer Ingelheim International GmbH100$95,262
Boehringer Ingelheim Pharma GmbH & Co.kg10$87,188
Boston Scientific37$9,549
Sanofi US Services Inc.2$5,838
Abbott60$3,815
Organon1$2,500
Medtronic(2 entities)19$1,519
Novo Nordisk AS45$1,323
Biotronik Inc.30$1,317
Bayer13$1,283
Lexicon Pharmaceuticals, Inc.4$1,095
Boehringer Ingelheim5$451
Philips North America LLC14$376
E.r. Squibb & Sons, L.L.C.21$359
Johnson & Johnson21$357
Pfizer20$324
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)18$267
Esperion Therapeutics, Inc.10$189
Lilly USA, LLC3$188
Cvrx, Inc.8$182
Sanofi-aventis U.S. LLC8$164
BD1$133
Biosense Webster, Inc.2$113
Astellas Pharma US Inc3$109
Kestra Medical Technology Services, Inc.2$87
Alnylam Pharmaceuticals Inc.3$66
Novo Nordisk3$63
Cardiva Medical, Inc.2$48
Amarin Pharma, Inc.2$42
Cardiovascular Systems Inc.2$38
Bard Peripheral Vascular, Inc.2$33
Shockwave Medical, Inc1$30
Baxter Healthcare2$28
Regeneron Healthcare Solutions, Inc.2$27
Stryker1$20
Actelion Pharmaceuticals US, Inc.1$19
Kiniksa Pharmaceuticals International, PLC1$18
Abiomed1$18
Edwards Lifesciences1$17
Irhythm Technologies, Inc.1$16
Reflow Medical Inc1$16
Angiodynamics, Inc.1$15
Elutia, Inc.1$14
Amryt Pharma Holdings Ltd1$13

How this compares

$3,985,016 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida →

Medicare billing

Part B allowed, 2024
$763,203
Medicare patients
1,519
Services billed
9,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Port Charlotte

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →